← back to search

William J. Fulp

Fred Hutch Cancer Center · US
Area of research
Oncology · Cancer Research
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Breast Cancer Treatment Studies, Cervical Cancer and HPV Research, and Cholangiocarcinoma and Gallbladder Cancer Studies.
h-index
50
citations
7,541
works
256
NIH funding
primary concept
email

Recent publications

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
npj Vaccines 2024cited by 39position: middledoi
Vaccination induces HIV broadly neutralizing antibody precursors in humans
Science 2022cited by 265position: middledoi
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
Frontiers in Immunology 2022cited by 3position: middledoi
Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization.
2021cited by 48position: contributordoi
The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis.
2021cited by 36position: contributordoi
Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer?
2021cited by 22position: contributordoi
Impact of Axillary Dissection Among Patients With Sentinel Node-Positive Breast Cancer Undergoing Mastectomy.
2021cited by 17position: contributordoi
Surgeon Bias in the Management of Positive Sentinel Lymph Nodes.
2021cited by 2position: contributordoi
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
2021cited by 2position: contributordoi
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates
Science Immunology 2020cited by 148position: middledoi
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.
2020cited by 132position: contributordoi
Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.
2020cited by 18position: contributordoi
Oral HPV prevalence assessment by Linear Array vs. SPF<sub>10</sub> PCR-DEIA-LiPA<sub>25</sub> system in the HPV Infection in Men (HIM) study.
2020cited by 14position: contributordoi
Variability of CD4+ Cell Counts in HIV-1-Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine Study.
2020cited by 1position: contributordoi
Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases.
2019cited by 21position: contributordoi
Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy.
2019cited by 18position: contributordoi
Human Papillomavirus Genotype Detection in Oral Gargle Samples Among Men With Newly Diagnosed Oropharyngeal Squamous Cell Carcinoma.
2019cited by 15position: contributordoi
Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.
2019cited by 6position: contributordoi
Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy
Journal of Gastrointestinal Oncology 2017cited by 16position: middledoi
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study
The Lancet Oncology 2016cited by 467position: middledoi
Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study
The Journal of Infectious Diseases 2016cited by 127position: middledoi
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
Clinical Cancer Research 2012cited by 210position: middledoi
Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data
Annals of Oncology 2012cited by 61position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Anna R. Giuliano · Moffitt Cancer Center4 papers (2019–2020)Eric A. Mellon · Henry Ford Health System2 papers (2016–2017)Javier F. Torres–Roca · Moffitt Cancer Center2 papers (2012–2016)Steven A. Eschrich · Moffitt Cancer Center2 papers (2012–2016)John A. Foekens · European Bioinformatics Institute2 papers (2012–2016)Xiaoying Shen · Ministry of Education of the People's Republic of China1 papers (2022–2022)Eduardo Lazcano‐Ponce · Australian National University1 papers (2016–2016)Michael J. Schell · Moffitt Cancer Center1 papers (2016–2016) · 1 papers (2012–2012)William S. Dalton · Moffitt Cancer Center1 papers (2016–2016)Jimmy J. Caudell · Moffitt Cancer Center1 papers (2016–2016)Kamran A. Ahmed · Moffitt Cancer Center1 papers (2016–2016)Nicole L. Yates · Duke University1 papers (2022–2022)Eduardo G. Moros · Charité - Universitätsmedizin Berlin1 papers (2016–2016)John W.M. Martens · Erasmus MC1 papers (2012–2012)Alicia Sato · Seattle University1 papers (2022–2022)Greg Finak · Fred Hutch Cancer Center1 papers (2020–2020)Anthony D. Cristillo · University of California System1 papers (2022–2022)Jonas Bergh · Karolinska Institutet1 papers (2012–2012)Susan W. Barnett · Novartis (Switzerland)1 papers (2022–2022)